TRuST: A phase 1 and 2 trial to assess the long-term safety of the tazemetostat

This trial will provide continuing availability to tazemetostat for people that have previously received it in other trials, and will assess its long-term safety.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT02875548
 

Trial aim and background  

The aim of this trial is to provide continuing access to the treatment tazemetostat. This is for people that have previously received it in a tazemetostat trial, are continuing to get benefit from it, and not experiencing any unacceptable side-effects.

Part of this study is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter 

Adults who are currently receiving tazemetostat either on its own, or in combination with other approved medications may be eligible for this trial.

Locations 

Recruitment to this trial is by invitation only but is taking place in the following locations:

  • Beatson West of Scotland Cancer Centre, Glasgow
  • Oncology and Haematology Clinical Trials Unit, Leicester
  • Clatterbridge Cancer Centre, Liverpool
  • Hammersmith Hospital, London
  • The Christie NHS Foundation Trust, Manchester

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT02875548

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.